Surgical management of foot malformations due to neurofibromatosis type 1. Case report

Authors

  • Nathaly Patiño-Vargas Universidad Libre (Cali Campus), Faculty of Health Sciences, Medical Program, Santiago de Cali, Colombia. https://orcid.org/0009-0004-0176-6697
  • Juan Pablo López-García Universidad del Valle, Faculty of Health, School of Medicine, Santiago de Cali, Colombia. https://orcid.org/0009-0000-3570-1665
  • Carlos Enrique Ramírez-Dávila Universidad del Valle, Faculty of Health, Specialty in Orthopedics and Trauma Surgery, Santiago de Cali, Colombia. | Pontificia Universidad Javeriana Cali and Clínica Imbanaco, Permanent Professional Development Program: Foot and Ankle Surgery, Colombia. https://orcid.org/0000-0002-4040-681X
  • Mauricio Zuluaga-Botero Universidad del Valle, Faculty of Health, Specialty in Orthopedics and Trauma Surgery, Santiago de Cali, Colombia. | Pontificia Universidad Javeriana Cali and Clínica Imbanaco, Santiago de Cali, Colombia. https://orcid.org/0000-0003-0023-458X
  • Paola Andrea Kafury-Goeta Pontificia Universidad Javeriana Cali and Clínica Imbanaco, Santiago de Cali, Colombia. | Universidad del Valle, Faculty of Health, Plastic Surgery Specialty Program: Reconstructive and Aesthetic Surgery, Santiago de Cali, Colombia. https://orcid.org/0009-0007-3011-6003
  • Carlos Andrés Lores-Restrepo Universidad del Valle, Faculty of Health, Specialty in Orthopedics and Trauma Surgery, Santiago de Cali, Colombia. | Pontificia Universidad Javeriana Cali and Clínica Imbanaco, Santiago de Cali, Colombia. https://orcid.org/0000-0002-4736-0201

DOI:

https://doi.org/10.58814/01208845.105

Keywords:

Rare Deseases, Neurofibromatoses, Genes, Neurofibromatosis 1, Neurofibroma

Abstract

Introduction: Neurofibromatosis (NF) is a neurocutaneous syndrome that can affect various organs and systems. It is classified as a rare or orphan disease, and its management represents a clinical challenge.

Case presentation: A 33-year-old female patient with malformations in both feet characterized by the presence of rapidly growing exophytic masses since the age of 3, who had undergone multiple surgeries for the removal of said masses, presented to the Orthopedics Department of a tertiary care hospital in Cali (Colombia) due to lesion recurrence. Based on findings from the physical examination and imaging studies, she was diagnosed with neurofibromatosis type 1 (NF1), meeting four of the National Institutes of Health diagnostic criteria. After determining that the right foot was the most affected, surgical management was initiated with four procedures performed over a period of 31 days: resection of a giant neurofibroma, resection of residual tumors, amputation of the fourth toe of the right foot along with coverage of the plantar surface using a reverse-flow fasciocutaneous flap from the superficial sural artery and skin grafts with placement of a hybrid external fixator as a protective measure for the flap and grafts, and management of small plantar areas using split-thickness skin grafts. Four months after the last intervention, adequate healing and maturation of the flaps and grafts were observed, with no evidence of lesion recurrence, so surgery was scheduled for the management of NF1-related lesions on the left foot.

Conclusion: Based on the results obtained in our patient, it could be stated that accurate diagnosis and multidisciplinary management by specialists in orthopedics and trauma surgery and plastic surgery are highly important for successfully treating NF1-related lesions in the feet, resulting in satisfactory functional and aesthetic outcomes and the subsequent improvement in quality of life.

Downloads

Download data is not yet available.

References

Tamura R. Current understanding of neurofibromatosis type 1, 2, and schwannomatosis. Int J Mol Sci. 2021;22(11):5850. doi: 10.3390/ijms22115850. PMID: 34072574; PMCID: PMC8198724.

Le C, Thomas A, Lui F. Neurofibromatosis. [Updated 2025 May 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. PMID: 29083784.

Colombia. Ministerio de Salud y Protección Social. Resolución 0023 de 2023, por la cual se actualiza el listado de enfermedades huérfanas - raras. Available from: https://bit.ly/3HGnTv6.

Gunes D, Karaca M, Durmus A, Ak B, Aktay-Ayaz N, Altınel ZU, et al. Challenges in the clinical management of rare diseases and center-based multidisciplinary approach to creating solutions. Eur J Pediatr. 2025;184(5):281. doi: 10.1007/s00431-025-06101-z. PMID: 40186762; PMCID: PMC11972228.

Correa MF, Pasic NI. Neurofibromatosis tipo 1 y 2. Rev. Hosp. Ital. B.Aires. 2019;39(4):115-27.

Ly KI, Blakeley JO. The Diagnosis and Management of Neurofibromatosis Type 1. Med Clin North Am. 2019;103(6):1035-54. doi: 10.1016/j.mcna.2019.07.004. PMID: 31582003.

Jordan JT, Plotkin SR. Neurofibromatoses. Hematol Oncol Clin North Am. 2022;36(1):253-67.

doi: 10.1016/j.hoc.2021.08.010. PMID: 34756486.

Combemale P, Lion-François L, Pinson S. Neurofibromatosis de tipo 1 y formas variantes. EMC - Dermatol. 2019;53(3):1-12. doi: 10.1016/S1761-2896(19)42817-3.

Gómez M, Batista O. Neurofibromatosis tipo 1 (NF1) y su diagnóstico molecular como estrategia del diagnóstico diferencial y a edades tempranas. Rev. Méd. Chile. 2015;143(10). doi: 10.4067/S0034-98872015001000011.

Bildirici Y, Kocaaga A, Karademir-Arslan CN, Yimenicioglu S. Evaluation of molecular and clinical findings in children with neurofibromatosis type 1: Identification of 15 novel variants. Pediatr Neurol. 2023;149:69-74. doi: 10.1016/j.pediatrneurol.2023.08.036. PMID: 37806041.

Carcavilla A, Ezquieta B. Guía para pacientes con síndrome de Noonan y otras RASopatías y sus familiares. España: Asociación Síndrome de Noonan de Cantabria; 2015. Available from: https://bit.ly/4e0qVGq.

Miraglia E., Moliterni E., Iacovino C., Roberti V., Laghi A., Moramarco A, Giustini S. Cutaneous manifestations in neurofibromatosis type 1. Clin Ter. 2020;171(5):e371-e377. doi: 10.7417/CT.2020.2242. PMID: 32901776.

Hernández A, Duat A. Neurofibromatosis tipo 1: más que manchas café con leche, efélides y neurofibromas. Parte I. Actualización sobre criterios dermatológicos diagnósticos de la enfermedad. Actas Dermosifiliogr. 2016;107(6):454-64. doi: 10.1016/j.ad.2016.01.004.

Hirbe A, Gutmann D. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol 2014;13:834-43. doi: 10.1016/S1474-4422(14)70063-8. PMID: 25030515.

Ozarslan B, Russo T, Argenziano G, Santoro C, Piccolo V. Cutaneous Findings in Neurofibromatosis Type 1. Cancers (Basel). 2021;13(3):463. doi: 10.3390/cancers13030463. PMID: 33530415; PMCID: PMC7865571.

Messersmith L, Krauland K. Neurofibroma. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. PMID: 30969529.

Hernández A, Duat A. Neurofibromatosis tipo 1: más que manchas café con leche, éfélides y neurofibromas. Parte II. Actualización sobre otras manifestaciones cutáneas características de la enfermedad. NF1 y cáncer. Actas Dermosifiliogr. 2016;107(6):465-73. doi: 10.1016/j.ad.2016.01.009.

Published

2025-06-29

How to Cite

1.
Patiño-Vargas N, López-García JP, Ramírez-Dávila CE, Zuluaga-Botero M, Kafury-Goeta PA, Lores-Restrepo CA. Surgical management of foot malformations due to neurofibromatosis type 1. Case report. Rev. Colomb. Ortop. Traumatol. [Internet]. 2025 Jun. 29 [cited 2026 Mar. 14];39:e105. Available from: https://revistasccotorg.biteca.online/index.php/rccot/article/view/105

Issue

Section

Case report
Article metrics
Abstract views
Galley vies
PDF Views
HTML views
Other views
Crossref Cited-by logo
Escanea para compartir
QR Code